Prestige Consumer Healthcare (NYSE:PBH) Sets New 52-Week High - Still a Buy?

Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) reached a new 52-week high during trading on Friday . The stock traded as high as $88.58 and last traded at $88.79, with a volume of 51799 shares changing hands. The stock had previously closed at $87.09.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on PBH shares. Canaccord Genuity Group boosted their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a report on Friday, February 7th. Sidoti downgraded Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective for the company. in a report on Monday, December 9th. Raymond James raised Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. DA Davidson lifted their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Finally, StockNews.com raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Friday, January 24th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $92.60.

Remove Ads

Prestige Consumer Healthcare Stock Performance

The company has a 50-day simple moving average of $80.80 and a two-hundred day simple moving average of $77.88. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The firm has a market cap of $4.41 billion, a PE ratio of 20.87, a PEG ratio of 2.69 and a beta of 0.46.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. As a group, equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Kestra Investment Management LLC purchased a new position in Prestige Consumer Healthcare in the fourth quarter worth $27,000. CIBC Private Wealth Group LLC lifted its position in shares of Prestige Consumer Healthcare by 48.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock valued at $34,000 after buying an additional 152 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of Prestige Consumer Healthcare during the 4th quarter valued at $40,000. Huntington National Bank lifted its position in shares of Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company's stock valued at $46,000 after buying an additional 181 shares during the last quarter. Finally, McIlrath & Eck LLC lifted its position in shares of Prestige Consumer Healthcare by 19.1% during the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock valued at $75,000 after buying an additional 154 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.